- Phase 1
- Phase 2
- Phase 3
Diabetic Macular Edema,
Retinal Neovascular Disease
EB-101, EB-102, EB-105, and EB-107
Retina: Wet AMD, Diabetic Macular Edema, Diabetic Retinopathy, Pre-IND
EB-101, EB-102, EB-105, and EB-107 are preclinical stage assets under development for wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and diabetic retinopathy (DR). These first-in-class biologics leverage state-of-the-art advances in antibody engineering and are specifically designed to address the multifactorial biology of angiogenesis and diabetic vasculopathy beyond current anti-VEGF therapies. Our goal with these molecules is to provide the next generation of treatment for age- and diabetes-related eye diseases and potentially other anti-VEGF responsive retinal diseases (e.g., retinal vein occlusion (RVO), and polypoidal choroidal vasculopathy (PCV), providing improved durability, fewer intravitreal injections and alterative options for patients with sub-optimal or refractory responses to anti-VEGF therapy alone. These molecules are wholly developed and owned by Eluminex Biosciences.
Cornea: Corneal Blindness, Phase 3
EB-301 is a novel clinical stage first-in-class biosynthetic cornea derived from recombinant human collagen and is in late-stage development initially for the China market. EB-301 is intended for the treatment of visual acuity deficits associated with corneal blindness due to stable, non-infectious stromal lesions amenable to anterior lamellar keratoplasty (ALK) as an alternative to cadaveric human donor cornea. A lack of available donor human corneas is a significant issue in China. Approximately 8,000 donor corneal transplants are conducted in China annually but there are an estimated 150,000 to 200,000 new patients per year that are eligible for corneal transplantation. EB-301 has several potential advantages over currently available porcine corneal implants including improved corneal clarity, no need for immunosuppressants, and serve as a tissue scaffold to allow ingrowth of surrounding stromal and epithelial tissue. Prior clinical studies have shown encouraging long term (> 4 years) durability with improved visual acuity and no corneal melt. Eluminex Biosciences has obtained the exclusive global license for the development of EB-301 from FibroGen (South San Francisco, CA).
Reference: Fagerholm, et al. Stable corneal regeneration four years after implantation of a cell-free recombinant human collagen scaffold. Biomaterials (2014) 35:2420-27.